19 research outputs found
Recommended from our members
Orbit: A Code for Collective Beam Dynamics in High Intensity Rings.
We are developing a computer code, ORBIT, specifically for beam dynamics calculations in high-intensity rings. Our approach allows detailed simulation of realistic accelerator problems. ORBIT is a particle-in-cell tracking code that transports bunches of interacting particles through a series of nodes representing elements, effects, or diagnostics that occur in the accelerator lattice. At present, ORBIT contains detailed models for strip-foil injection, including painting and foil scattering; rf focusing and acceleration; transport through various magnetic elements; longitudinal and transverse impedances; longitudinal, transverse, and three-dimensional space charge forces; collimation and limiting apertures; and the calculation of many useful diagnostic quantities. ORBIT is an object-oriented code, written in C++ and utilizing a scripting interface for the convenience of the user. Ongoing improvements include the addition of a library of accelerator maps, BEAMLINE/MXYZPTLK, the introduction of a treatment of magnet errors and fringe fields; the conversion of the scripting interface to the standard scripting language, Python; and the parallelization of the computations using MPI. The ORBIT code is an open source, powerful, and convenient tool for studying beam dynamics in high-intensity rings
Π§ΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΊ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Π°ΠΌ ΠΈ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΠΎΡΠ²Π΅ΡΠ° ΠΊΠ»Π΅ΡΠΎΠΊ in vitro Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
Inhaled corticosteroids are widely used for the treatment of chronic obstructive pulmonary disease (COPD), but their efficacy significantly varies between patients. The aim of the study was to establish approaches to reveal steroid-sensitive and steroid-resistant patients with COPD using the blood and lung cells. Methods. Forty five patients with COPD undergoing bronchoscopy were recruited for the study of cytokine secretion by alveolar macrophages under the influence of glucocorticoids. Alveolar macrophages isolated from bronchoalveolar lavage fluid were cultured with lipopolysaccharide (LPS) and different concentrations of dexamethasone (0.01 β 1000 nM) for 24 h. Then, supernatants were removed and analyzed for concentrations of interleukin 6 (IL-6), IL-8 and tumor necrosis factor Ξ± (TNF-Ξ±). Binding of the glucocorticoid with its receptors was investigated in 24 patients with COPD, 20 healthy smokers and 20 healthy non-smokers. Blood cells were cultured with fluorescein isothiocyanate (FITC)-labelled dexamethasone and monoclonal antibodies against surface antigens of lymphocyte and monocyte populations. Fluorescence intensity of FITC-labelled dexamethasone was analyzed in blood cells using flow cytometry. Results. Dexamethasone significantly inhibited IL-6, IL-8, and TNF-Ξ± production in alveolar macrophages in a dose dependent manner. The maximal inhibition of cytokine production was observed at dexamethasone concentration of 100 nM, and the maximal cell response variability was found at 10 nM. IL-8 was less sensitive to the corticosteroid compared to IL-6 and TNF-Ξ±. Dexamethasone at any concentration failed to reach >50% inhibition of LPS-induced production of IL-8, IL-6 and TNF-Ξ± in alveolar macrophages of 40.0%; 11.1% and 8.9% of COPD patients, respectively. The fluorescence intensity of FITC-labelled dexamethasone in blood lymphocytes and monocytes was lower in smokers with COPD compared to healthy smokers and healthy non-smokers. The binding of dexamethasone with its receptors in the blood cells was higher in healthy non-smokers compared to healthy smokers. Conclusion. In vitro response of alveolar macrophages to glucocorticoids in COPD patients is characterized by significant inter-individual variability. The weak corticosteroid-related inhibition of IL-8 production can contribute to neutrophilic inflammation in COPD. The capacity of glucocorticoid receptors to bind with their ligands in blood lymphocytes and monocytes is decreased in COPD patients.ΠΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΡΠ΅ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Ρ (ΠΈΠΠΠ‘) ΡΠΈΡΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ), ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ°Π·Π»ΠΈΡΠ°Π΅ΡΡΡ. Π¦Π΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»ΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ, ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈ Π½Π΅ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΊ ΠΠΠ‘, ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ Π»Π΅Π³ΠΊΠΈΡ
ΠΈ ΠΊΡΠΎΠ²ΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½-ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΡΡΡΠ΅ΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² (ΠΠ) ΠΏΠΎΠ΄ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΠΌ ΠΠΠ‘ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ (n = 45), ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½ΡΠ»Π°ΡΡ Π±ΡΠΎΠ½Ρ
ΠΎΡΠΊΠΎΠΏΠΈΡ. ΠΠ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅ ΠΈΠ· Π±ΡΠΎΠ½Ρ
ΠΎΠ°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΠΎΠΉ Π»Π°Π²Π°ΠΆΠ½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ, ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Ρ Π»ΠΈΠΏΠΎΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄ΠΎΠΌ ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΠΌΠΈ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° (0,01β1Β 000 Π½Π). ΠΠΎ ΠΈΡΡΠ΅ΡΠ΅Π½ΠΈΠΈ 1 ΡΡΡΠΎΠΊ ΡΠΎΠ±ΠΈΡΠ°Π»ΠΈΡΡ ΡΡΠΏΠ΅ΡΠ½Π°ΡΠ°Π½ΡΡ, Π² Π½ΠΈΡ
ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»Π°ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π° (IL)-6, IL-8 ΠΈ ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ-Ξ± (TNF-Ξ±). ΠΠ»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΠΠ‘ ΠΈ ΠΈΡ
ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 24), Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ ΠΊΡΡΠΈΠ»ΡΡΠΈΠΊΠΈ (n = 20) ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ Π½Π΅ΠΊΡΡΡΡΠΈΠ΅ (n = 20). ΠΠ»Π΅ΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Ρ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½ΠΎΠΌ, ΠΌΠ΅ΡΠ΅Π½Π½ΡΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅ΠΈΠ½ΠΈΠ·ΠΎΡΠΈΠΎΡΠΈΠ°Π½Π°ΡΠΎΠΌ (FITC) ΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΠΌΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ ΠΊ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠ½ΡΠΌ Π°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠΎΠ². ΠΠ½Π°Π»ΠΈΠ· ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ FITC-ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎ ΡΠ½ΠΈΠΆΠ°Π»Π°ΡΡ ΡΠ΅ΠΊΡΠ΅ΡΠΈΡ IL-6, IL-8 ΠΈ TNF-Ξ± ΠΠ. ΠΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΠ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΠΏΡΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° 100 Π½Π, Π° Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ°Ρ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΎΡΠ²Π΅ΡΠ° ΠΊΠ»Π΅ΡΠΎΠΊ β ΠΏΡΠΈ 10 Π½Π. IL-8 Π±ΡΠ» ΠΌΠ΅Π½Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»Π΅Π½ ΠΊ ΠΈΠΠΠ‘, ΡΠ΅ΠΌ IL-6 ΠΈ TNF-Ξ±. ΠΡΠΈ Π»ΡΠ±ΠΎΠΉ ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½ Π½Π΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π» Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Π½Π° 50 % ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ IL-8 Π² ΠΠ Ρ 40 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ, IL-6 β Ρ 11,1 %, TNF-Ξ± β Ρ 8,9 %. Π£ ΠΊΡΡΡΡΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ FITC-ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΊΡΡΡΡΠΈΡ
ΠΈ Π½Π΅ΠΊΡΡΡΡΠΈΡ
Π·Π΄ΠΎΡΠΎΠ²ΡΡ
. Π‘Π²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΠΎ ΡΠ²ΠΎΠΈΠΌΠΈ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ°ΠΌΠΈ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ Π±ΡΠ»ΠΎ Π²ΡΡΠ΅ Ρ Π½Π΅ΠΊΡΡΡΡΠΈΡ
Π·Π΄ΠΎΡΠΎΠ²ΡΡ
, ΡΠ΅ΠΌ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΠΊΡΡΠΈΠ»ΡΡΠΈΠΊΠΎΠ². ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π₯ΠΠΠ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΌΠ΅ΠΆΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΉ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΡΡ in vitro ΠΎΡΠ²Π΅ΡΠ° ΠΠ Π½Π° ΠΠΠ‘. ΠΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΠ½ΡΠ΅Π·Π° IL-8 ΠΠΠ‘ ΠΌΠΎΠΆΠ΅Ρ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ Π₯ΠΠΠ. ΠΠ»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΡΠ²ΠΎΠΉΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΠΠ‘-ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΡΠ²ΡΠ·ΡΠ²Π°ΡΡΡΡ ΡΠΎ ΡΠ²ΠΎΠΈΠΌΠΈ Π»ΠΈΠ³Π°Π½Π΄Π°ΠΌΠΈ Π² Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ
ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ
OPEN XAL Status Report 2015
MOPW1050International audienceOpen XAL is an accelerator physics software platformdeveloped in collaboration among several facilitiesaround the world. The Open XAL collaboration wasformed in 2010 to port, improve and extend the successfulXAL platform used at the Spallation Neutron Source foruse in the broader accelerator community and to establishit as the standard platform for accelerator physicssoftware. The site-independent core is complete, activeapplications have been ported, and now we are in theprocess of verification and transitioning to using OpenXAL in production. This paper will present the currentstatus and a roadmap for this project
Open XAL status Report 2015
Open XAL is an accelerator physics software platform developed in collaboration among several facilities around the world. The Open XAL collaboration was formed in 2010 to port, improve and extend the successful XAL platform used at the Spallation Neutron Source for use in the broader accelerator community and to establish it as the standard platform for accelerator physics software. The site-independent core is complete, active applications have been ported, and now we are in the process of verification and transitioning to using Open XAL in production. This paper will present the current status and a roadmap for this project
Recommended from our members
Accelerator Physics Code Web Repository
In the framework of the CARE HHH European Network, we have developed a web-based dynamic acceleratorphysics code repository. We describe the design, structure and contents of this repository, illustrate its usage, and discuss our future plans, with emphasis on code benchmarking
ΠΠΠΠΠ’Π ΠΠΠ‘ΠΠΠΠΠ’ΠΠ¦ΠΠ― ΠΠΠ-ΠΠΠ‘ΠΠΠΠΠ‘Π’ΠΠΠ«Π₯ ΠΠΠ§ΠΠ Π£ ΠΠΠ’ΠΠ
At present the problem of donor organs for transplantation shortage remains unsolved. Cautious and mixed attitude towards the transplantation of incompatible kidneys remains, while it could considerably reduce the donor organ waiting time for a recipient. Experience of 19 allotransplantations of ABO-incompatible kidneys in children is analyzed in the article. A group of 14 patients who received ABOcompatible kidneys was chosen for the comparative analysis. Such parameters as the assessment of function of allotransplanted kidneys, morphology character comparison of biopsy materials of allo-kidneys in both groups, actuarial survival rate of the recipients with functioning allografts are used to assess the results. Comparison of the aforementioned parameters showed practically the same results, and that enables us to assert that transplantations of kidneys of ABO-incompatible donors have the right to exist.Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΎΡΡΠ°Π΅ΡΡΡ Π½Π΅ΡΠ΅ΡΠ΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π½Π΅Ρ
Π²Π°ΡΠΊΠΈ Π΄ΠΎΠ½ΠΎΡΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² Π΄Π»Ρ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ. Π‘ΠΎΡ
ΡΠ°Π½ΡΠ΅ΡΡΡ Π½Π°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΠ΅, Π½Π΅ΠΎΠ΄Π½ΠΎΠ·Π½Π°ΡΠ½ΠΎΠ΅ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΊ ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠ΅ Π½Π΅ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
ΠΏΠΎΡΠ΅ΠΊ, ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΠΌΠΎΠ³Π»ΠΎ Π±Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠΎΠΊΡΠ°ΡΠΈΡΡ Π²ΡΠ΅ΠΌΡ ΠΎΠΆΠΈΠ΄Π°Π½ΠΈΡ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠΌ Π΄ΠΎΠ½ΠΎΡΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π°. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½ ΠΎΠΏΡΡ 19 Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΉ ΠΠ0-Π½Π΅ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
ΠΏΠΎΡΠ΅ΠΊ Ρ Π΄Π΅ΡΠ΅ΠΉ. ΠΠ»Ρ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π²ΡΠ±ΡΠ°Π½Π° Π³ΡΡΠΏΠΏΠ° ΠΈΠ· 14 Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Ρ ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠΈ ΠΠ0-ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
ΠΏΠΎΡΠ΅ΠΊ. ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΡΠ°ΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ, ΠΊΠ°ΠΊ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠ½ΠΊΡΠΈΠΈ Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎΡΠ΅ΠΊ, ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² Π°Π»Π»ΠΎΠΏΠΎΡΠ΅ΠΊ Π² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
, ΠΎΡΠ΅Π½ΠΊΠ° Π°ΠΊΡΡΠ°ΡΠ½ΠΎΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΡΡΡΠΈΠΌΠΈ Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°ΠΌΠΈ. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π²ΡΡΠ΅ΠΏΠ΅ΡΠ΅ΡΠΈΡΠ»Π΅Π½Π½ΡΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ, ΡΡΠΎ Π΄Π°Π΅Ρ Π½Π°ΠΌ ΠΏΡΠ°Π²ΠΎ ΡΡΠ²Π΅ΡΠΆΠ΄Π°ΡΡ: ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠΈ ΠΏΠΎΡΠ΅ΠΊ ΠΎΡ ΠΠ0-Π½Π΅ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈΠΌΠ΅ΡΡ ΠΏΡΠ°Π²ΠΎ Π½Π° ΡΡΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠ΅
Anemia in renal allograft recipients
The review deals with anemia, one of the posttransplantation complications. To define the ways of preventing this complication in the posttransplantation period, the factors favors its development are analyzed. Anemia is shown to negatively affect autografted kidney function and actuarial survival in allokidney graft recipients. The current principles in the treatment of posttransplantation anemia are reflected
Measurement of longitudinal acceptance and emittance of the Oak Ridge Spallation Neutron Source Superconducting Linac
Generation of donor-specific immunotolerance in renal-allograft recipients
The kidney cannot be successfully grafted without immunosuppressive therapy. A unicenter retrospective study has evaluated the efficiency of immunosuppression with daclizumab (Zenapax) versus alemtuzumab (Campath).Subjects and methods. After renal allotransplantation, 64 patients, including 34 and 30 patients, were treated with daclizumab and alemtuzumab, respectively. The absolute count of peripheral blood lymphocytes was measured. Renal grafts were morphologically assessed as described by Banff.Results. After administration of alemtuzumab, there was a more pronounced decrease in the absolute count of peripheral blood lymphocytes and the rate of acute rejection crisis was 1.5 times lower than that after use of daclizumab.Conclusion. During the study, alemtuzumab demonstrated a more marked immunosuppressive activity than did daclizumab and the ability of the former to generate donor-specific immunotolerance in renal-allograft recipients